T-3262 IN EXTERNAL EYE DISEASES AND ITS PENETRATION INTO HUMAN TEAR

DOI
  • YATA KOJI
    Department of Ophthalmology, School of Medicine, Kyorin University
  • SHIMIZU CHIHIRO
    Department of Ophthalmology, School of Medicine, Kyorin University
  • ISHIWATA TAKETSUGU
    Department of Ophthalmology, School of Medicine, Kyorin University
  • TOKUDA HISAYA
    Department of Ophthalmology, School of Medicine, Kyorin University

Bibliographic Information

Other Title
  • 眼科学領域におけるT-3262の臨床的・基礎的検討

Abstract

T-3262, a new pyridone-carboxylic acid derivative, was administered to a total of 21 patients, namely, 19 with meibomitis and 2 with hordeolum, to evaluate its clinical efficacy. The drug was given at 75 or 150 mg 2-3 times a day after meals, and the duration of administration ranged 1. 5-8 days. Clinical efficacy was excellent in 12 patients, good in 7 and fair in 2, the efficacy rate being 90.5%. As for adverse events, diarrhea was observed in one patient. It was however, mild and rapidly disappeared on the day after withdrawal of T-3262.<BR>After a single dose of 150 mg given after a meal to healthy volunteers, T-3262 levels in tear and serum were determined. The peak T-3262 level in tear was achieved at about 2h after dosing, and the mean peak level was 0.165μg/ml, which corresponded to about 20% of the mean serum level of 0.84μg/ml obtained at the time.

Journal

  • CHEMOTHERAPY

    CHEMOTHERAPY 36 (Supplement9-Clinical), 1426-1429, 1988

    Japanese Society of Chemotherapy

Keywords

Details 詳細情報について

Report a problem

Back to top